Start with the exact product, facility, patient destination and transaction—not a supplier category. FDA distinguishes compounded preparations from approved drugs and explains that the oversight and quality requirements differ between qualifying 503A compounding and 503B outsourcing. A compounder’s registration or a pharmacy relationship should therefore not be treated as product approval. (fda.gov)
Use the interviews in this order:
| Decision gate | Questions | Required output |
|---|---|---|
| What arrangement are we evaluating? | 1 | Product, responsibility and money-flow map |
| Is the proposed route supportable? | 2–4 | Product-specific legal assessment and destination-state evidence |
| Can we assess quality and provenance? | 5–7 | Facility evidence register, handling controls and traceability responsibilities |
| Does access work economically and operationally? | 8–11 | Workflow comparison, matched quotations and measurable service commitments |
| Can we withstand disruption and leave safely? | 12–16 | Tested fallback, clinical transition plan and reviewed contracts |
Recommended procurement rule: Keep unresolved route-eligibility and critical quality questions outside price-weighted rankings. Record them as approval gates rather than allowing a low quotation to offset missing evidence.
Explore the table row by row
A working view of the research
What arrangement are we evaluating?
- Questions
- 1
- Required output
- Product, responsibility and money-flow map
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers